The primary objective of this trial is to investigate the safety and tolerability of BI 639667 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality as well as investigation of linearity and pharmacodynamics (PD) of BI 639667 after single dosing and the assessment of the PK/PD relationship.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Number of subjects with drug-related adverse events
Time frame: up to 19 days postdose
AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time frame: up to 120 hours postdose
Cmax (maximum measured concentration of the analyte in plasma)
Time frame: up to 120 hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.